Colin Walsh

Abingworth Management Ltd. operates as an investment firm with interests in the life sciences and healthcare sectors. It offers services for businesses in all stages of company development, including early and late-stage venture financing, growth equity, and public companies. The company was founded in 1973 and is headquartered in London, the United Kingdom.

Abingworth Bioventures VI LP invests in private and public companies located the US and Europe. The fund targets companies operating in the fields of medical devices, instrumentation, bio therapeutics, small molecules, nucleic acid therapeutics, vaccines, specialty pharma, technologies, diagnostics and software. The fund provides financing for seed, early and late stage capital requirements with an investment size of $15 - $30 million. It seeks Majority or minority investments in the companies.

Abingworth LLP (Abingworth) is a venture capital firm founded in the year 1973 Peter Dickson and Anthony Montagu. The firm headquartered in London and additional offices in San Francisco and Boston. Abingworth LLP became part of The Carlyle Group Inc. (NASDAQ: CG) on 3rd August 2022.

The Institute of Chartered Accountants in England & Wales ensures that its members, students, and affiliates maintain the highest standards of professional competency and conduct to protect the public interest. The non-profit company is based in London, UK, and has subsidiaries in the United Kingdom. With over 150,000 members, the institute provides technical information, helplines, and communities to its members.

Credit Suisse Securities (Europe) Ltd. (Credit Suisse Europe) is the Great Britain-based brokerage subsidiary of Credit Suisse Investment Holdings (UK), itself a subsidiary of Credit Suisse Group AG (SWX: CSGN) in Switzerland. The firm was founded in 1966 and formerly known as Credit Suisse First Boston (Europe) Ltd. Headquartered in London, Credit Suisse Europe arranges financing in international capital markets, provides financial advisory services and acts as a dealer in securities, derivatives and foreign exchange on a principal and agency basis for corporate and institutional investors.

HSBC Bank Plc (Broker) (HSBC Bank-Broker) is the broker/dealer division of HSBC Bank Plc, which is owned by HSBC Holdings Plc (LON: HSBA; NYSE: HSBC) in Great Britain. Headquartered in London, HSBC Bank-Broker was founded in 1880 and offers bespoke brokerage services across every major asset class for their corporate and institutional clients.

venBio Partners LLC (venBio) is a venture capital subsidiary of Venbio Partners LP founded in 2009 by Adelman robert and Goodman corey. The firm is headquartered in San Francisco, California.

Integra Holdings Ltd. operates as a holding company. It invests in the pharmaceutical industry. The company was founded in 2012 and is headquartered in Jerusalem, Israel.

Enso Ventures Ltd (Enso Ventures) is an independent venture capital firm founded in 2010 by Nikolay Danilov. The firm is headquartered in London, United Kingdom.

Snoody Ltd. develops and supplies antiviral and healing technology for various product applications. It provides wound dressings, mastitis prevention products, ulcer preventing socks, face masks, and integrated pathogen defense products. The company was founded in 2009 by Paul Francis Hope and is headquartered in Manchester, the United Kingdom.

SparingVision SAS develops therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa. The company was founded by Jose Alain Sahel, Thierry Leveillard and Florence Allouche Ghrenassia and is headquartered in Paris, France.

Arrakis Therapeutics, Inc. operates as a biopharmaceutical company. It develops rna-targeted small molecule medicines focused on neurologic, cancer, and rare genetic diseases. The company was founded by Russell C. Petter, Alan E. Walts, Jennifer C. Petter and Raj Bhikhu Parekh in 2015 and is headquartered in Waltham, MA.

Arkin Bio Ventures (Arkin Bio) is a venture capital arm of Arkin Holdings founded in 2016. The firm is headquartered in Tel Aviv, Israel.

Aeovian Pharmaceuticals, Inc. engages in the development of pharmaceuticals. It offers inhibitors for the treatment of rare and age-related diseases. The company was founded by Stelios T. Tzannis in 2012 and is headquartered in Novato, CA.

NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands.

4BIO Ventures Management Ltd (4bio Capital Partners) is an independent venture capital firm founded in 2014 by Andrey Kozlov. The firm headquartered in London, United Kingdom.

Stargazer Pharmaceuticals, Inc. manufactures pharmaceutical products. The firm engages in the development of treatment for Stargardt’s disease, a rare form of juvenile, retinal degeneration. The company was founded by Gary Jay Sternberg and is headquartered in Boston, MA.

Auron Therapeutics, Inc. operates as a biotechnology company. It aims to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells. The company was founded by Kate Yen, Matt Vander Heiden, Ross Levine, and Eytan Stein and is headquartered in Wellesley, MA.

Lutris Pharma Ltd. is working on the improvement of the anti-cancer therapy effectiveness and the quality of life for patients that are treated with Epidermal Growth Factor Receptor Inhibitors. The company was founded on December 14, 2015 and is headquartered in Tel Aviv, Israel.

Arkin Holdings engages in the provision of healthcare investment services which specializes in pharmaceutical and biotechnology, medical devices, dermatology, and hedge fund. The company was founded by Mori Arkin in 2009 and is headquartered in Herzliya, Israel.

Attralus, Inc. operates as a biopharmaceutical company. The firm focuses on illuminating the systemic nature of amyloidosis and creating transformative medicines to improve the lives of patients. The company was founded by Jonathan Wall in 2019 and is headquartered in San Francisco, CA.

Pharvaris GmbH operates as a clinical-stage company. It specializes in medicinal chemistry, drug discovery and development and hereditary angioedema. The company was founded by Berndt A. E. Modig, Jochen Knolle, Anne Lesage and Hans G. C. P. Schikan in October 2015 and is headquartered in Zug, Switzerland.

Bluejay Therapeutics, Inc. is a clinical stage private biopharmaceutical company that is committed to developing effective treatments and cures for viral and liver diseases. The company is based in San Mateo, CA, and was founded by Keting Chu, who has been the CEO since incorporation. The company's first target indication is chronic hepatitis b, which is a worldwide prevalent disease with an urgent unmet medical need. Bluejay is advancing two innovative approaches with the potential for a high rate of functional cure: fully human igg1 anti-hbs monoclonal antibodies and first-in-class hbsag oral small molecule inhibitors. The company believes that by reducing hepatitis b surface antigen and restoring adaptive immunity, a functional cure could be achieved for patients.

35Pharma, Inc. designs and develops biologics for diseases of high unmet medical need. The CEO of the Canadian company is Ilia A. Tikhomirov.

Paros Bio, Inc. is a private company that specializes in gene therapy for neurodegenerative diseases. The company is based in Boston, MA. The company is focused on developing a gene replacement approach to treat autosomal dominant Alzheimer's disease (ADAD). Specifically, they are working on a gene therapy that targets mutations in the presenilin 1 gene (PSEN1), which is the underlying genetic cause of ADAD.

Entact Bio, Inc. is a company that focuses on creating new medicines by enhancing protein function. The company is based in Watertown, MA. The company is a team of scientists, entrepreneurs, drug creators, and problem solvers who work together to bring new medicines to patients who currently have few options. The CEO of the company is Victoria M. Richon. The founder of the company grew up in chaos and instability in an undisclosed capital city and has always been passionate and motivated to help enhance and provide medical solutions.

Disruptive Capital Finance LLP (Disruptive Capital) is a private equity firm founded in 2006 by Cédriane Marie de Boucaud Truell, Edmund George Truell and Roger Le Tissiermr. The firm is headquartered in London.